№ lp_1_2_53041
File format: docx Character count: 26616 File size: 489 KB
Policy outlines the role of the IBD CNSp in the management of patients on biologic medication, detailing the necessary pre-screening steps, patient education, and the overall responsibility of the medical team involved.
Year: 2019
Region / City: Naas General Hospital
Topic: Inflammatory Bowel Disease, Biologic Medication
Document Type: Policy
Author: Joanna Rea, Inflammatory Bowel Disease Clinical Nurse Specialist
Target Audience: IBD CNSp, Gastroenterology team, nursing staff administering biologic medication
Approval Date: 14th January 2020
Revision Date: January 2023
Version Number: 1
Supporting Evidence: Infliximab, Remicade, Vedolizumab, Adalimumab, Imraldi, Amgevita, Hulio, Golimumab, Ustekinumab
Purpose: Standardization of pre-screening and management of IBD patients requiring biologic treatment
Scope: Biologic screening, patient education, IBD CNSp, gastroenterology team, nursing staff
Objective(s): Ensure best practice for IBD patients on biologics
Outcome(s): Clarity for staff on safe and evidence-based care for IBD patients on biologics
Governance: IBD Working Group
Review Group: Not Applicable
Date of Approval: 14th January 2020
Date of Next Revision: January 2023
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Informed Consent for Emergency Use/Treatment with an Unapproved Drug / Biologic / Device 16.315 (HRP-506)
Note: Year
Subject: Emergency Use Treatment
Document Type: Informed Consent Form
Executive summary: The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs
Year: 2025
Region / city: UK
Topic: Rheumatology, Axial Spondyloarthritis
Document type: Guideline
Organization / institution: British Society for Rheumatology
Author: Sizheng Steven Zhao, Stephanie R Harrison, Ben Thompson, Max Yates, Joe Eddison, Antoni Chan, Nick Clarke, Nadia Corp, Charlotte Davis, Lambert Felix, Kalveer Flora, William J Gregory, Gareth T Jones, Christopher A Lamb, Helena Marzo-Ortega, Daniel J Murphy, Harry Petrushkin, Virinderjit Sandhu, Raj Sengupta, Stefan Siebert, Danielle A Van Der Windt, Dale Webb, Zenas Z N Yiu, Karl Gaffney
Target audience: Health professionals, rheumatologists
Period of validity: Ongoing
Approval date: 2025
Date of changes: Not specified
Context: This is a clinical guideline for treating axial spondyloarthritis with biologic and targeted synthetic DMARDs.
FedBizOpps Special Notice - Award of Contracts under Solicitation 36C10G18R0003 for Biologics and Biologic Implants
Year: 2018
Region / City: Fredericksburg, VA
Topic: Biologics, Contracting, Medical Supplies
Document Type: Contract Award Notice
Agency: U.S. Department of Veterans Affairs
Author: Not specified
Target Audience: Contractors, Veterans Affairs
Period of Action: From September 27, 2018
Approval Date: September 27, 2018
Date of Changes: Not specified
INTERACT Meeting Package for Biologic XY Development Program Submission to FDA
Year: 2026
Region / City: United States, Silver Spring, MD
Subject: Drug and Biologic Product Development
Document Type: Meeting Package
Organization / Institution: U.S. Food and Drug Administration (FDA)
Author: Sponsor Investigator, MD, Professor, Department of University of California, Los Angeles
Target Audience: FDA Reviewers, CBER/CDER Staff
Submission Date: 2026
Meeting Type: INTERACT
Product Name: Biologic XY
Product Description: Adenoviral vector expressing human cDNA with 1 and 2 region deletions
Proposed Indication: Treatment or prevention of specific disease or condition
Content Sections: Introduction, Product Development Summary, Purpose of Meeting, Specific Questions, Supporting Data, Proposed Agenda, Sponsor Attendees, Suggested Dates, Meeting Format, References
Job Description for Temporary Consultant General Surgeon at Naas General Hospital
Year: 2023
Country: Ireland
Region: Kildare / West Wicklow
City: Naas
Institution: Naas General Hospital
Hospital Group: Dublin Midlands Hospital Group
Type of document: Job description
Position title: Temporary Consultant General Surgeon
Contract type: Public Only Consultant Contract 2023
Employment basis: Temporary specified purpose
Working hours: 37 hours per week
Department: Surgery
Specialty: General Surgery
Healthcare setting: Acute general hospital
Associated academic institution: Trinity College Dublin
Remuneration basis: Department of Health approved salary scale
Pension scheme: Single Public Service Pension Scheme
Eligibility requirements: Medical Council of Ireland specialist registration in General Surgery
Health requirements: Occupational Health clearance and compliance with blood-borne disease screening
Age requirement: Under 65 years for non-new entrants
Probation: Subject to satisfactory completion of probationary period
Annual leave entitlement: 30 working days per annum (pro rata)
Governing legislation: Organisation of Working Time Act 1997
On-call arrangements: B and C factor on-call payments applicable
EVALUATION FOR NAAS SCORING OF RESEARCH JOURNALS WITH NO IMPACT FACTOR EFFECTIVE FROM 01.01.2024
Year: 2023
Region / City: New Delhi
Topic: Agriculture, Research Journals
Document Type: Guidelines
Organ / Institution: National Academy of Agricultural Sciences
Author: Not specified
Target Audience: Publishers of Research Journals
Period of Validity: Effective from 01.01.2024
Approval Date: Not provided
Date of Amendments: Not provided
EVALUATION FOR NAAS SCORING OF RESEARCH JOURNALS WITH NO IMPACT FACTOR EFFECTIVE FROM 01.01.2025
Year: 2023
Region / city: New Delhi
Topic: Agricultural Research Journals Evaluation
Document type: Guideline
Organization / institution: National Academy of Agricultural Sciences
Author: NAAS
Target audience: Publishers of agricultural research journals
Period of validity: From 01.01.2025
Approval date: Not specified
Date of amendments: Not specified
Grade VII Clinical Risk Manager Job Specification and Terms and Conditions, Naas General Hospital
Year: 2026
Country: Ireland
Region / City: Naas, County Kildare
Institution: Naas General Hospital
Health Region: Dublin and Midlands Health Region
Department: Quality & Patient Safety Department
Document Type: Job Specification and Recruitment Notice
Position Title: Grade VII Clinical Risk Manager
Grade Code: 0582
Campaign Reference: NAAS-01-26-13
Closing Date: 10 February 2026, 12:00 noon
Proposed Interview Notice Period: Normally at least two weeks
Employment Type: Permanent whole-time vacancy with potential panel for future full-time or part-time posts
Salary Scale (effective 01 August 2025): €60,013 – €78,015 with incremental progression and Long Service Increments
Reporting To: Quality & Patient Safety Manager
Key External Stakeholders: HSE Legal Advisors, State Claims Agency, Coroner’s Office
Service Area: Hospital risk management, patient safety, and clinical governance
Hospital Capacity: Approximately 250 beds including acute inpatient, day beds, and inpatient psychiatry beds
Population Served: Kildare, West Wicklow, and surrounding areas
Topics: PPPG Biologic Naas